Advertisement

Advertisement

ASCO 2022: Adding ASCT to Triplet/Maintenance Therapy for Newly Diagnosed Multiple Myeloma
Posted: 06/07/2022 | By: Chase Doyle

Question 1 of 5

In the phase III DETERMINATION trial, the addition of autologous stem cell transplantation (ASCT) to lenalidomide, bortezomib, and dexamethasone followed by lenalidomide maintenance to progression improved median progression-free survival by how many months (vs lenalidomide, bortezomib, and dexamethasone plus lenalidomide maintenance alone)?

Choose 1